Abstract |
Competitive inhibitors of lysosomal hydrolases (pharmacological chaperones) have been used to treat some lysosomal storage diseases which result from mis-sense mutations and mis-folded protein but have not been tried in Batten disease, for which there is no current therapy. We synthesized a large number of novel, non-hydrolyzable competitive inhibitors of palmitoyl:protein thioesterase (PPT1) and showed that some could act as chemical chaperones. One inhibitor (CS38: betaAGDap(Pal)VKIKK) was taken up by lymphoblasts from patients with mutations leading to the T75P/R151X substitutions and enhanced PPT1 activity 2-fold. A similar 2-fold stimulation with another inhibitor (AcGDap(Palm)GG(R)(7)) was observed in patients with a G108R amino acid substitution in PPT1. Residual PPT1 activity in both was thermally unstable at pH 7.4 (but not at 4.7) consistent with a mis-folded, unstable PPT1 degraded by the ER stress response. Patients with null mutations did not respond to the pharmacological chaperones.
|
Authors | Glyn Dawson, Christina Schroeder, Philip E Dawson |
Journal | Biochemical and biophysical research communications
(Biochem Biophys Res Commun)
Vol. 395
Issue 1
Pg. 66-9
(Apr 23 2010)
ISSN: 1090-2104 [Electronic] United States |
PMID | 20346914
(Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
|
Copyright | 2010 Elsevier Inc. All rights reserved. |
Chemical References |
- Enzyme Inhibitors
- Membrane Proteins
- Molecular Chaperones
- Thiolester Hydrolases
- PPT1 protein, human
|
Topics |
- Cell Line
- Enzyme Inhibitors
(chemistry, pharmacology, therapeutic use)
- Enzyme Stability
(genetics)
- Humans
- Membrane Proteins
(antagonists & inhibitors, genetics, metabolism)
- Molecular Chaperones
(chemistry, pharmacology, therapeutic use)
- Neuronal Ceroid-Lipofuscinoses
(drug therapy, enzymology)
- Point Mutation
- Protein Folding
(drug effects)
- Thiolester Hydrolases
|